Ruopeng Su

发表

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation

J. Qi, Zhou Jiang, Qi Wang, 2022, Frontiers in Oncology.

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy

Minfeng Chen, Jiwei Huang, Yichu Yuan, 2022, Oncoimmunology.

Breast cancer metastasis to the stomach may misdiagnose as primary gastric cancer : report of one case and review of literature

Xing-qiang Yan, Zhao-sheng Ma, F. Cao, 2016 .

How Many Contralateral Carcinomas in Patients with Unilateral Papillary Thyroid Microcarcinoma are Preoperatively Misdiagnosed as Benign?

Xing-qiang Yan, Zenggui Wu, Ruoxi Su, 2016, World Journal of Surgery.

Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway

Lei Chen, Yinjie Zhu, Qi Wang, 2023, Cellular oncology.

High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer

Yinjie Zhu, Zehua Ma, Lei Chen, 2023, Frontiers in Oncology.

Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study

Minfeng Chen, Jiwei Huang, Yichu Yuan, 2023, Cancer medicine.

Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy.

Minfeng Chen, Jiwei Huang, W. Xue, 2023, Urologic oncology.

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

B. Dong, H. Zhu, Yinjie Zhu, 2023, Nature communications.